Subutex (buprenorphine) is considered a first-line treatment for opioid use disorder during pregnancy. Both the American College of Obstetricians and Gynecologists (ACOG) and the Substance Abuse and Mental Health Services Administration (SAMHSA) recommend buprenorphine, alongside behavioral therapy, as a preferred medication for pregnant women managing opioid dependence. It is not risk-free, but the evidence consistently shows that treated pregnancies have better outcomes than untreated opioid use disorder.
Why Subutex Over Suboxone During Pregnancy
Subutex contains only buprenorphine, while Suboxone combines buprenorphine with naloxone. During pregnancy, the buprenorphine-only formulation is generally recommended because there is limited safety data on how the combination product affects a developing baby. The naloxone component is included in Suboxone to discourage misuse, but its effects during pregnancy haven’t been studied enough to confirm it’s equally safe. For this reason, most prescribers switch patients to buprenorphine alone when pregnancy is confirmed or being planned.
Birth Defect Risk
A large study published in JAMA Internal Medicine found that the overall rate of major congenital malformations with first-trimester buprenorphine exposure was about 51 per 1,000 births. For comparison, the rate with methadone was roughly 61 per 1,000. That translates to about one fewer affected baby for every 100 pregnancies treated with buprenorphine instead of methadone. Cardiac malformations specifically occurred at a rate of 14 per 1,000 with buprenorphine versus 23 per 1,000 with methadone.
To put these numbers in context, the background rate of major birth defects in the general U.S. population is about 30 per 1,000 births. So buprenorphine does carry a modestly elevated risk, but it remains within a range that medical organizations consider acceptable given the serious dangers of untreated opioid use disorder during pregnancy.
What Happens to the Baby After Birth
The most common concern is neonatal abstinence syndrome (NAS), a withdrawal reaction that can occur in newborns after prenatal opioid exposure. About 50 to 55% of babies exposed to buprenorphine alone develop NAS severe enough to need medical treatment. That’s a meaningful number, but it’s significantly lower than the 81 to 85% rate seen with methadone.
When NAS does occur in buprenorphine-exposed infants, hospital stays tend to be shorter. Babies exposed only to buprenorphine averaged about 24 days in the hospital, compared to roughly 36 days for those exposed to methadone alone. NAS symptoms typically include tremors, excessive crying, poor feeding, and sleep disturbances. Hospital staff monitor newborns closely and provide treatment to keep them comfortable, gradually weaning them as symptoms resolve.
Long-Term Development in Exposed Children
A population-based study tracking children over several years found that 17% of those exposed to buprenorphine early in pregnancy were later diagnosed with a neurodevelopmental condition, compared to 36% of children exposed to methadone. When researchers compared buprenorphine-exposed children to unexposed children, the differences were much smaller than those seen with methadone. The study’s authors concluded that buprenorphine appears to be a good treatment option during pregnancy with minimal long-term neurodevelopmental impact, though they noted that factors like environment and other substance exposure can be difficult to fully separate from the medication’s effects.
Why Stopping Opioids Cold Turkey Is Not Recommended
It might seem logical that quitting opioids entirely would be safest for the baby, but medical guidelines specifically advise against supervised withdrawal during pregnancy. Opioid withdrawal causes dramatic shifts in the body’s stress hormones and can trigger uterine contractions, raising the risk of preterm labor and fetal distress. There is also a high relapse rate after withdrawal, which often leads to a dangerous cycle of abstinence followed by return to use at unpredictable doses. Maintaining a stable, controlled dose of buprenorphine keeps both the mother and fetus in a physiologically steady state.
Untreated opioid use disorder during pregnancy increases the likelihood of fetal growth problems, preterm delivery, and complications like placental abruption. It also makes consistent prenatal care much harder to maintain. Pregnancies involving active opioid use typically require additional monitoring, including extra ultrasounds to check fetal growth and expanded testing for sexually transmitted infections.
Dose Changes During Pregnancy
Your body processes buprenorphine differently as pregnancy progresses. Blood levels of the medication drop significantly during the second and third trimesters compared to the non-pregnant state, even at the same dose. This happens because of increased blood volume, faster metabolism, and changes in how the liver processes the drug. Many women notice withdrawal-like symptoms creeping in as their pregnancy advances, which is a sign the dose may need adjustment.
Research suggests that splitting the daily dose into twice-daily dosing, or increasing the total dose, can help maintain stable drug levels throughout the day. If you’re feeling symptoms of withdrawal between doses, this is worth discussing with your prescriber rather than assuming you need to tough it out. Keeping buprenorphine levels steady benefits both you and the baby.
Pain Management During Labor and Delivery
One practical concern many women have is whether they’ll be able to get adequate pain relief during labor while on buprenorphine. The answer is yes, though it requires some planning. Buprenorphine partially blocks opioid receptors, which means standard pain medications may be less effective at typical doses. Epidurals and other regional anesthesia options work normally and are the preferred approach for labor pain.
After delivery, pain from vaginal birth or cesarean section can be managed with a combination of anti-inflammatory medications and short-acting opioid painkillers given at adjusted doses. Research confirms that patients on buprenorphine do respond to additional opioid pain medication. The key is making sure your labor and delivery team knows about your buprenorphine use well in advance so they can plan accordingly.
Breastfeeding on Buprenorphine
Buprenorphine passes into breast milk in very small amounts. Studies consistently show that a breastfed infant receives less than 1% of the mother’s weight-adjusted dose, with estimates ranging from about 0.2% to 1.4% depending on the study. On top of that, buprenorphine is poorly absorbed through an infant’s digestive tract, meaning even less reaches their bloodstream.
Because of these low exposure levels, breastfeeding is actively encouraged for women who are stable on buprenorphine and not using other substances. Breastfeeding may actually help ease NAS symptoms in newborns by providing small, consistent amounts of the medication along with the comfort and bonding of nursing. You should watch for unusual drowsiness, difficulty feeding, breathing changes, or limpness in your baby, though these reactions are uncommon. If you stop breastfeeding abruptly, your baby could experience mild withdrawal symptoms, so gradual weaning is preferable.